Objectives: Pancreatic islet transplantation requires multiple transplants to achieve insulin independence. Only one third of the islet mass is stably engrafted; one of the causes of which is ascribed to oxidative stress. We confirmed the hypothesis that administration of edaravone, a free radical scavenger, in the early posttransplantation period promotes islet cell engraftment.
Methods: Islet isograft from a single donor was intraportally transplanted into streptozotocin-diabetic F344 rats, and intravenous edaravone (3 mg/kg) was administered immediately and 24 hours after the transplantation. Plasma glucose concentrations were monitored for 28 days. Serum insulin levels were obtained on the second week. Morphologic studies were performed on insulin-immunostained and TUNEL-stained sections of the recipient liver.
Results: In the edaravone-treated group, hyperglycemia was ameliorated, and 50% of rats achieved normoglycemia (<200 mg/dL). All rats in the control group remained hyperglycemic (>400 mg/dL). Insulin secretion of the edaravone-treated group was superior to the controls. Morphologically, the number and size of the islet β cells of the edaravone-treated group were larger than those of the controls. The number of TUNEL-positive cells in each islet of the edaravone-treated group were fewer than those of the controls.
Conclusions: In streptozotocin-diabetic rats, edaravone administration in the early posttransplantation period promotes engraftment of intraportally transplanted islet cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPA.0b013e3181f7e436 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between edaravone use and activities of daily living in older patients with atherothrombotic stroke: an observational study using Japanese real-world data.
BMC Geriatr
January 2025
Department of Pharmacy, Faculty of Pharmacy, Musashino University, 1-1-20 Shinmachi Nishitokyo-Shi, Tokyo, 202-8585, Japan.
Background: Edaravone is marketed in nine countries, although only Japan has approved edaravone for improvement of neurological symptom, disability of activities of daily living (ADL), and functional disability associated with acute stroke. This study aimed to elucidate the association of edaravone use with ADL using real-world data of older patients with atherothrombotic stroke.
Methods: This retrospective observational research using the Medical Data Vision database in Japan included patients aged 65 years and older who had acute ischemic stroke of the atherothrombotic subtype.
Efficacy of Radicava® IV (intravenous edaravone) in subjects with differing trajectories of disease progression in amyotrophic lateral sclerosis: Use of a novel statistical approach for post hoc analysis of a pivotal phase 3 clinical trial.
J Neurol Sci
December 2024
Mitsubishi Tanabe Pharma America, Inc., 525 Washington Blvd., Ste 1100, Jersey City, NJ 07310, United States. Electronic address:
Introduction: Subjects with amyotrophic lateral sclerosis (ALS) treated with Radicava® (edaravone) IV (intravenous; Mitsubishi Tanabe Pharma America [MTPA], hereafter "MTPA IV edaravone") in Study MCI186-19 had a significantly slower physical functional decline vs placebo-treated subjects as measured by the revised ALS Functional Rating Scale (ALSFRS-R) and analyzed by the linear mixed model for repeated measures (MMRM). This Study 19 post hoc analysis of MTPA IV edaravone-treated and placebo-treated subjects evaluated linear and nonlinear latent class mixed models defining trajectories based on identifying the model with the lowest Bayesian information criterion. The best model differentiated 4 nonlinear trajectories in ALS subjects.
View Article and Find Full Text PDFIntravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis.
EClinicalMedicine
October 2022
Medical Affairs, Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ, United States.
Background: We aimed to evaluate overall survival in US patients with amyotrophic lateral sclerosis (ALS) treated with intravenous (IV) edaravone compared with those not treated with IV edaravone in a real-world setting.
Methods: This exploratory retrospective comparative effectiveness observational analysis included patients with ALS who were enrolled in an administrative claims database from 8 August 2017 to 31 March 2020. Propensity score matching identified IV edaravone-treated patients (cases) and non-edaravone-treated patients (controls) matched for covariates: age, race, geographic region, sex, pre-index disease duration, insurance, history of cardiovascular disease, riluzole prescription, gastrostomy tube placement, artificial nutrition, noninvasive ventilation, and all-cause hospitalisation.
Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Clin Ther
August 2020
Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
Purpose: Two studies were conducted to assess the pharmacokinetic (PK) properties and tolerability of edaravone in Japanese subjects with mild to moderate hepatic impairment or normal hepatic functioning (study 1), and in white subjects with severe hepatic impairment compared to subjects with normal hepatic functioning (study 2).
Methods: Studies 1 and 2 were multicenter, open-label, single-dose studies that included subjects aged 18-75 years. In study 1, subjects were stratified into 3 different groups of hepatic functioning according to Child-Pugh score: mild hepatic impairment, score 5 or 6 (n = 8); moderate hepatic impairment, score 7-9 (n = 6); or normal hepatic functioning (n = 8).
Antioxidant nanomedicine with cytoplasmic distribution in neuronal cells shows superior neurovascular protection properties.
Brain Res
September 2020
Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, Japan; Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, Japan.
Article Synopsis
- This study examines the effectiveness of nitroxide radical-containing nanoparticles (RNPs) in preventing damage from reactive oxygen species (ROS) after cerebral ischemia-reperfusion in mice.
- RNPs were compared to edaravone and a control group regarding survival rates, neurological outcomes, and their ability to protect the blood-brain barrier.
- Results showed RNPs improved survival and neurological function more than edaravone, reduced blood-brain barrier disruption, and enhanced the beneficial M2 polarization of microglia, suggesting RNPs as a promising therapeutic option for neuroprotection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!